Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full.
Kereiakes
Dean J
DJ
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D017700:Embolism, Cholesterol / Q000209:etiology* / Q000517:prevention & control; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007431:Intraoperative Complications; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012107:Research Design; D012306:Risk; D012501:Saphenous Vein / Q000473:pathology / Q000637:transplantation; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab